Telix Pharmaceuticals (NASDAQ:TLX) Reaches New 1-Year Low – Here’s Why

Telix Pharmaceuticals Limited (NASDAQ:TLX)’s share price reached a new 52-week low during trading on Monday . The company traded as low as $8.68 and last traded at $8.66, with a volume of 53394 shares. The stock had previously closed at $9.03.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on TLX shares. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Telix Pharmaceuticals in a research report on Thursday, August 28th. UBS Group lowered their price target on Telix Pharmaceuticals from $23.00 to $20.00 and set a “buy” rating on the stock in a report on Tuesday, September 23rd. Royal Bank Of Canada began coverage on Telix Pharmaceuticals in a research note on Monday. They issued a “hold” rating for the company. Citigroup started coverage on Telix Pharmaceuticals in a research note on Thursday, September 18th. They set a “buy” rating and a $22.00 target price on the stock. Finally, Wedbush reissued an “outperform” rating and issued a $22.00 price target on shares of Telix Pharmaceuticals in a research report on Thursday, August 28th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Telix Pharmaceuticals has an average rating of “Moderate Buy” and a consensus target price of $21.00.

Telix Pharmaceuticals Stock Down 7.2%

The business has a fifty day moving average of $9.92 and a 200 day moving average of $12.03.

Institutional Investors Weigh In On Telix Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the business. Millennium Management LLC acquired a new stake in shares of Telix Pharmaceuticals in the third quarter worth about $1,883,000. Pier Capital LLC bought a new position in shares of Telix Pharmaceuticals in the 2nd quarter valued at approximately $3,037,000. Portland Investment Counsel Inc. acquired a new stake in Telix Pharmaceuticals in the 3rd quarter worth approximately $1,225,000. Lazard Asset Management LLC bought a new stake in Telix Pharmaceuticals during the third quarter worth approximately $1,097,000. Finally, Russell Investments Group Ltd. acquired a new position in Telix Pharmaceuticals during the second quarter valued at approximately $975,000.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals.